Drug Trial Radar · NCT06644183
Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL)
Last checked: Nov 19, 2026Latest source record: Feb 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
64
Planned (sponsor's estimate)
Start
Mar 19, 2025
Primary completion
Oct 1, 2028
Study completion Oct 1, 2032
Sponsor
- Lead sponsor
- Jennifer R. Brown, MD, PhDAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- United States Department of Defense
- First posted
- Oct 16, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a novel type of PI3-kinase delta inhibitor) * Venetoclax (a type of B-cell lymphoma 2 inhibitor) * Rituximab (a type of monoclonal antibody)
Conditions
- Leukemia
- Relapsed Leukemia
- Chronic Lymphocytic Leukemia
- Relapsed Cancer
- Refractory Leukemia
Interventions
RoginolisibDrug
Phosphoinositide 3-kinase delta inhibitor, 40 mg capsule, taken orally per protocol.
VenetoclaxDrug
B-cell lymphoma 2 inhibitor, 10, 50, and 100mg tablets, taken orally per standard of care.
RituximabDrug
Chimeric anti-CD 20 monoclonal antibody, single-use 10 and 50mL vials, via intravenous (into the vein) infusion per standard of care.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Undetectable Minimal Residual Disease(uMRD) rate by ClonoSEQ assayTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Dana-Farber Cancer Institute
Boston, Massachusetts · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.